News | May 29, 2021
IPCA Q4FY21 consolidated net profit slides QoQ to Rs. 161.34 Cr
The company has posted net profit of Rs.1140.01 crores during FY 2020-21
The company has posted net profit of Rs.1140.01 crores during FY 2020-21
The patients can check to see if the product purchased by them is genuine or not by scratching the surface and verifying the code through the app or the website
It posted net profit of Rs.60.96 crores for the 12 months period ended March 31, 2021
Mucormycosis drug AmphoTLC will be imported from Taiwan by Stelis Biopharma Private Limited (Stelis), the biotech arm of Strides group, and will be launched and distributed in India immediately by Strides
Dr. Sharvil Patel cites the example of prescriptions being handed over to patients despite unavailability of enough stock of such medicines
It is expected that the drug substance would be available from August 2021 which will be supplied back to Bharat Biotech for producing COVAXIN
Cadila Healthcare has reported total income of Rs.15139.4 crores FY 2020-21
Strides Pharma Science reported total income of Rs.3367.29 crores during FY 2020-21
The roller coaster ride during the pandemic has taken Indian pharmaceutical industry through a lot of bitter sweet experiences.
The company reported net profit for FY21 at Rs. 2,903.8 crore, lower by 23% over last year
Subscribe To Our Newsletter & Stay Updated
